-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1103 Aberrant Cell Cycle Programming Confers Rapid Lethality in the EuSOX11+ CCND1 MCL Mouse Model

Program: Oral and Poster Abstracts
Session: 621. Lymphoma—Genetic/Epigenetic Biology: Poster I
Hematology Disease Topics & Pathways:
Diseases, Lymphoma (any), Animal models, cell division, Mantle Cell Lymphoma, Non-Hodgkin Lymphoma, Biological Processes, Lymphoid Malignancies, Study Population, pathways
Saturday, December 5, 2020, 7:00 AM-3:30 PM

Donna R Edwards, MPH, PhD1*, Pei-yu Kuo, MS2*, Alessandro Lagana, PhD3,4,5*, Seongjee Park1*, Pavithra Nedumaran, MS1*, Violetta Leshchenko, PhD6*, Stephanie Christie, PhD7*, Shashidhar Jatiani, PhD8*, Julie Teruya-Feldstein, MD9 and Samir S. Parekh, MD10

1Icahn School of Medicine at Mount Sinai, New York, NY
2Department of Hematology and Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
3Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY
4Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York
5Institute for Next Generation Healthcare, Icahn School of Medicine at Mount Sinai, New York, NY
6Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
7Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY
8Mt Sinai Medical Center, New York, NY
9Department of Pathology, Molecular and Cell-Based Medicine, Hematopathology Division, Memorial Sloan-Kettering Cancer Center, New York, NY
10Department of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

Mantle Cell Lymphoma (MCL) is characterized by the t(11;14)(q13;q32) translocation. This hallmark oncogenic event transposes CCND1 (11q13) under the control of the immunoglobin heavy chain (IGH) locus (14q32) resulting in constitutive cyclin D1 expression. Although Cyclin D1 (CCND1) overexpression is a key hallmark of MCL, CCND1 overexpressing murine models do not effectively recapitulate the MCL phenotype. Our published data demonstrated that SOX11 binds and regulates components in multiple oncogenic pathways in MCL (Kuo et. al., Oncogene 2015). Furthermore, we recently demonstrated that SOX11 promotes BCR signaling to drive MCL-like pathogenesis utilizing a SOX11 overexpressing (Eu-SOX11) murine model (Kuo et. al., Blood 2018). Given that the majority of classic human MCL co-express CCND1 and SOX11, we hypothesize that these oncogenes may cooperate to drive the pathogenesis of classical MCL.

To study in vivo cooperation between CCND1 and SOX11, we crossed Eu-SOX11 mice with Eu-CCND1 mice to generate Eu-SOX11:CCND1 double transgenic (DT) mice. We have previously reported an significant increase in the fraction of CD5+CD19+CD23- MCL cells in the peripheral blood, spleens, lymph nodes and bone marrow of Eu-SOX11 mice and this fraction was further enhanced in DT mice (Fig.1A). We have now conducted a 2-year survival analysis on all 4 genotypes and found significantly reduced survival in DT as compared to Eu-SOX11 mice (Fig.1B). Median survival in DT mice is 16.5 months as compared to 19.7 months in Eu-SOX11 mice.

Taken together, our results demonstrate a B-cell specific in vivo cooperation between SOX11 and CCND1 towards promoting a lethal MCL phenotype. RNA sequencing of splenocytes from DT versus SOX11-Tg mice showed significant enrichment of E2F1 target genes (p<.02) as a top oncogenic pathway (Fig.1C). Our previous results with CDK4/6 inhibition demonstrate a profound reduction in S phase in MCL cells (Divakar et. al., Leukemia 2016).

We have developed small molecule SOX11 inhibitors using a SOX11-DNA homology model we built using the crystal structure of the SOX4-DNA binding domain as a template. SOX11 small molecular inhibitors in combination with CDK4 inhibitors will be used to further dissect the mechanism of cooperation between SOX11 and CCND1 and develop a therapeutic strategy for MCL that is mechanistically distinct from BTK or Bcl-2 inhibition.

Disclosures: Teruya-Feldstein: Edge Anthem: Consultancy. Parekh: Foundation Medicine: Consultancy; Celgene: Research Funding; Karyopharm: Research Funding.

*signifies non-member of ASH